article thumbnail

HHS Releases Unredacted Letter Confirming Agency’s Recommendation to DEA to Reclassify Marijuana to Schedule III

NORML

"It is significant for these health agencies to acknowledge publicly, for the first time, what many patients and advocates have known for decades: that cannabis is a safe and effective therapeutic agent for tens of millions of Americans."

DEA 317
article thumbnail

Survey: Majority of Health Care Professionals Endorse Cannabis Use Instead of Opioids in Chronic Pain Patients

NORML

Sixty-three percent of respondents also agreed, “The DEA should reclassify marijuana so that it is no longer a schedule I drug.". The post Survey: Majority of Health Care Professionals Endorse Cannabis Use Instead of Opioids in Chronic Pain Patients appeared first on NORML.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

USA: Dr Suing DEA Over Right To Give Patients Psilocybin Treatment

Cannabis Law Report

Marijuana Moment reports A Seattle doctor hoping to expand access to psilocybin mushrooms for terminally ill cancer patients is taking… Read More. The post USA: Dr Suing DEA Over Right To Give Patients Psilocybin Treatment first appeared on Cannabis Law Report.

DEA 85
article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

As cannabis enthusiasts, we’re all too familiar with the stigma surrounding its use and the hoops that have to be jumped through to get it into medical research trials. But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. So what gives?

DEA 98
article thumbnail

DEA Promises Progress on Federal Cultivation Applications, But Provides No Timetable for Action

NORML

The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.

DEA 168
article thumbnail

Cancer Patients Sue the DEA, Demand Psilocybin

SpeedWeed

CANNABIS CULTURE – Attorney Kathryn Tucker, who filed the petition said this is a first-of-its-kind lawsuit. The case is about seeking to ensure that patients with serious, life-threatening illness are able to realize the promise of state and federal Right to Try laws and access psilocybin for therapeutic purposes.”.

DEA 52
article thumbnail

Scientists Sue DEA as it Drags its Feet and Hampers Cannabis Research

WeedAdvisor

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle.

DEA 111